Incidence of COVID-19 mRNA vaccine symptomatic breakthrough infections during Omicron circulation in adults with or without infection prior to vaccination.
Fiche publication
Date publication
mars 2024
Journal
Infectious diseases now
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MUTTER Catherine
Tous les auteurs :
Durier C, Ninove L, van der Werf S, Lefebvre M, Desaint C, Bauer R, Attia M, Lecompte AS, Lachatre M, Maakaroun-Vermesse Z, Nicolas JF, Verdon R, Kiladjian JJ, Loubet P, Schmidt-Mutter C, Corbin V, Ansart S, Melica G, Resch M, Netzer E, Kherabi Y, Tardieu R, Lelièvre JD, Tartour E, Meyer L, de Lamballerie X, Launay O,
Lien Pubmed
Résumé
COVID-19 vaccine breakthrough infections were frequently reported during circulation of the Omicron variant. The ANRS|MIE CoviCompareP study investigated these infections in adults vaccinated and boosted with BNT162b2 [Pfizer-BioNTech] and with/without SARS-CoV-2 infection before vaccination.
Mots clés
Breakthrough infections, COVID-19 mRNA vaccine, Neutralization antibodies, Omicron
Référence
Infect Dis Now. 2024 03 15;:104886